Effects of Intravenous Injection and Intraperitoneal Continual
Administration Undigested dietary constituents such as nonstarch polysaccharide (dietary fiber) and registant starch escape digestion and absorption by the upper gastrointes tinal tract and reach the colon. Since these resistant carbohydrates are well fermented by anaerobic bacteria in the colon, dietary fiber and resistant starch have been suggested to be main substrate for the production of short-chain fatty acids (SCFAs) such as acetate, propionate, butyrate, and other products in humans and animals (1) (2) (3) (4) (5) . SCFAs are virtually totally abosrbed in the intestine and have been considered an energy source for the host (6) .
In addition to providing energy, SCFAs may strongly influence normal gastro intestinal function affecting colonic blood flow (7) , pancreatic secretion (8), sodium and water absorption in the colon (9) , and intestinal mucosal growth (10) . Moreover, Wright et al. reported that propionate can significantly inhibit cholester ol and fatty acid de novo synthesis in isolated rat hepatocytes (11) , Nishimura et al. recently demonstrated that SCFAs cecal content correlated negatively with plasma total-cholesterol levels in rats (12) .
In this study, to examine the effects of sodium propionate on serum cholesterol levels, both intravenous injection and intraperitoneal continual administration were performed in rats. sodium propionate, the serum level increased 0.1mg/ml. Thus, the incremental increase of serum sodium propionate levels following injection is higher than that of the above mentioned effective dose (11, 17) . Therefore, it is considered that the intensity of the reducing effect of sodium propionate on serum cholesterol reached a limit at 1mg. Likewise, the percentage of changes in serum triacylglycerol levels were significantly reduced by 0.1mg sodium propionate, with the reducing effect no longer enhanced at 1 or 10mg. Next, to elucidate the concern between propionate-mediated reduction of serum cholesterol and triacylglycerol levels and the hypocholesterolemic effects of certain soluble dietary fibers, intraperitoneal continual administration was ex amined. An osmotic pump was filled with a wide range of propionate concentra tions (0-11.5mg/day) and was implanted in the rats as an artificial cecum. At day 14, total-cholesterol levels were significantly reduced by both 0.12 and 1.2mg/day sodium propionate, as compared to saline alone. It is curious that HDL-cholesterol levels were reduced by saline similarly to that of sodium propionate. At day 21, 7 days after the osmotic pump was inactivated, the reducing effect of sodium propionate on serum cholesterol levels diminished. These observations suggest that intraperitoneal continual administration of sodium propionate can produce a significant reduction of serum total-cholesterol levels. Although serum tri acylglycerol levels were significantly reduced by intravenous sodium propionate injection, a similar tendency was not observed following intraperitoneal continual administration. The difference between the two types of administration is obscure.
In conclusion, the present data indicate that sodium propionate can reduce serum total-cholesterol levels in vivo.
